Vanguard Capital Management
PAVM icon

Vanguard Capital Management’s PAVmed PAVM Stock Holding History

Vanguard Capital Management’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Buy
61,604
+55,687
+941% +$394K ﹤0.01% 3760
2026
Q1 		$60.1K Buy
+5,917
New +$56K ﹤0.01% 3899

Other funds holding PAVM

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

Vanguard Capital Management's PAVM Position: Q2 2026 in Review

Vanguard Capital Management increased its PAVmed (PAVM) stake by 941% in Q2 2026, buying an estimated $394K and bringing the position to 61,604 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #3760.

Vanguard Capital Management first reported a position in PAVM in Q1 2026 and has held it in 2 quarters since. 19 funds tracked by Wall St. Rank hold PAVM as of Q2 2026.

  • Vanguard Capital Management held 61,604 shares of PAVmed worth $366K as of Q2 2026.
  • Vanguard Capital Management bought 55,687 PAVmed shares in Q2 2026, an estimated $394K.
  • PAVmed made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3760 holding.
  • Vanguard Capital Management first reported a position in PAVmed in Q1 2026 and has held it in 2 quarters since.
  • 19 funds tracked by Wall St. Rank held PAVmed as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.